Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A

NCT01480180 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

Congenital Bleeding Disorder
Haemophilia A

Interventions

DRUG: turoctocog alfa pegol

Sponsor

Novo Nordisk A/S